Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Innovations and highlights in the Pharma industry 

Dive deep into the world of Pharma with Zamann’s Expert Blog. Our industry-leading professionals share insights on global project management, quality consultancy, digitalization, and more. Stay updated with trends and innovations transforming the Pharma industry. 

News and more

Hidden flaw in pharmaceutical change control — a key driver slowing down drug approvals worldwide

A recent analysis by Megha Sinha of Kamet Consulting Group highlights post-approval life cycle change management as one of the most critical yet underdeveloped areas in pharmaceutical operations. With increasing regulatory complexity, global site transfers, and rising change volumes across
  • News
Hidden flaw in pharmaceutical change control — a key driver slowing down drug approvals worldwide

Big Pharma Is Losing Control of Production Sites — What Happens When CDMOs Take Over Billion-Dollar Manufacturing Assets?

Pharmaceutical manufacturing is undergoing a major structural shift as companies like GSK, Bristol Myers Squibb, and Sanofi sell production facilities to CDMOs. Reported in May 2026, this wave of asset transfers reflects rising GMP compliance costs, onshoring pressure, and demand
  • News
Big Pharma Is Losing Control of Production Sites — What Happens When CDMOs Take Over Billion-Dollar Manufacturing Assets?

EU Critical Medicines Act shocks the pharmaceutical supply chain — reshapes global pharmaceutical control frameworks

The European Union has reached a provisional agreement on the Critical Medicines Act (CMA) on May 13, 2026, marking a major shift in pharmaceutical policy toward supply chain sovereignty. The framework aims to reduce dependency on non-EU imports, strengthen domestic
  • News
EU Critical Medicines Act shocks the pharmaceutical supply chain — reshapes global pharmaceutical control frameworks

Small GMP Deviations, Massive Pharma Losses: Why One Failure Can Cost Over $1 Million

Pharmaceutical Technology’s PDA Week 2026 discussion highlights a critical shift in GMP manufacturing economics: the cost of quality failures escalates sharply depending on when defects are detected. From incoming inspection to final recall, even minor deviations can grow into million-dollar
  • News
Small GMP Deviations, Massive Pharma Losses: Why One Failure Can Cost Over $1 Million

AI Is Exposing Hidden Compliance Risks in Digital Pharma — Drug Approval at Risk

As artificial intelligence rapidly embeds itself across pharmaceutical manufacturing, R&D, and quality systems, it is no longer just driving efficiency, it is exposing a critical divide in digital maturity. Across GMP-regulated environments, AI is revealing hidden weaknesses in data integrity,
  • News
AI Is Exposing Hidden Compliance Risks in Digital Pharma — Drug Approval at Risk

Risk-Based Approach in GMP Inspection Compliance in 2026

Inspection findings in GMP environments increasingly stem from weak risk evaluation rather than missing procedures. This article explores GMP risk classification, pharmaceutical risk assessment, CAPA management, and audit readiness strategies that strengthen compliance and inspection performance across operations.
  • Blog, Quality Management System
Diagram showing GMP risk classification and pharmaceutical risk assessment workflow, including risk identification, evaluation, CAPA management, and audit readiness within a risk-based quality system.

FDA and EMA Just Changed AI Validation Rules — Pharma Compliance Is Shifting Fast

FDA and EMA have jointly released a new set of principles for the use of artificial intelligence in drug development, marking a major regulatory shift in how AI systems must be designed, validated, and governed in pharmaceutical environments.
  • News
FDA and EMA Just Changed AI Validation Rules — Pharma Compliance Is Shifting Fast

Hidden GMP Failure Detected in Inspection — Drug Approval Halted

A planned expansion of Regeneron’s flagship Eylea HD product has been rejected by the US FDA after a key fill-finish manufacturing site failed to meet GMP inspection standards, triggering a full regulatory setback and delaying a major lifecycle upgrade.
  • News
Hidden GMP Failure Detected in Inspection — Drug Approval Halted